ArticleJournal of Korean medical science2026
Circulating Estradiol as an Independent Risk Factor for Metabolic Dysfunction-Associated Steatotic Liver Disease and Fibrosis Risk in Women: Evidence From a Multicenter Health-Checkup Cohort.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06843421 (Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry: A Retrospective Multicenter Cross-Sectional Study (K-MASLD Registry)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) shows marked sexual dimorphism, with estrogen believed to be liver-protective. This study investigated the independent association between circulating estradiol levels, MASLD, and advanced fibrosis (defined by fibrosis index-4 [FIB-4] ≥ 1.3) in Korean women, utilizing stratified analyses by age and body mass index (BMI) to identify context-dependent effects.
methodsWe analyzed cross-sectional data from the Korean Health Screening-Based Metabolic Dysfunction-Associated Steatotic Liver Disease Registry, including 995 women (352 with MASLD). Multivariable logistic regression was used to evaluate the association of log2-transformed estradiol with MASLD and high-risk fibrosis, stratified by age (proxy for menopausal status, ≥ 50 vs. < 50 years) and BMI (≥ 25 vs. < 25 kg/m²).
resultsIn multivariable analysis of the entire cohort, lower estradiol levels were independently associated with MASLD (adjusted odds ratio [aOR], 0.88; 95% confidence interval [CI], 0.79-0.98;
conclusionLow circulating estradiol independently increases the risk of MASLD and high-risk fibrosis in women. While its protective effect against steatosis weakens with obesity, its antifibrotic effect remains strong across all subgroups. Estradiol may serve as an important hormonal marker for risk stratification in female MASLD patients.
trial registrationClinicalTrials.gov Identifier: NCT06843421.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.